Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

The introduction of novel agents has led to major improvements in clinical outcomes for
patients with multiple myeloma. To shorten evaluation times for new treatments, health …

High-throughput methods for slide-free three-dimensional (3D) pathological analyses of
whole biopsies and surgical specimens offer the promise of modernizing traditional …

Purpose Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by
intensifying chemotherapy for all patients. Minimal residual disease (MRD) levels during the …

Background Minimal residual disease (MRD) is the most sensitive and specific predictor of
relapse risk in children with acute lymphoblastic leukaemia (ALL) during remission. We …

In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been
developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) …

The persistence of minimal residual disease (MRD) during therapy is the strongest adverse
prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput …

Abstract The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-
Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the …

Purpose From 2002 to 2007, the International Berlin-Frankfurt-Münster Study Group
conducted a prospective randomized clinical trial (ALL IC-BFM 2002) for the management of …